Alpha Tau Medical (NASDAQ: DRTS) Prepares for Earnings Amid Positive Clinical Trial Results
- Alpha Tau Medical (NASDAQ: DRTS) is set to report earnings on November 19, 2026, with estimated earnings of -$0.15 per share and revenue of $125,000.
- Positive clinical results from the U.S. REGAIN trial for Alpha DaRT therapy showed objective responses in all six assessed glioblastoma patients, including five complete responses.
- Seeking Alpha maintains a Buy rating on Alpha Tau Medical, citing potential FDA approval in 2027 and other positive trial data, though it notes the small sample size of the REGAIN trial.
Alpha Tau Medical (NASDAQ: DRTS) develops a localized alpha-radiation platform. It is expected to report earnings before the market opens on November 19, 2026, with estimated earnings of -$0.15 per share and estimated revenue of $125,000.
Ahead of earnings, clinical results draw attention. In its U.S. REGAIN trial of Alpha DaRT therapy for recurrent glioblastoma, all six patients assessed by November 11, 2026, had an objective response, as highlighted by Benzinga. Five had complete responses, and one had a partial response with a 58% reduction in tumor measurements.
All eight treated patients were alive as of November 11, 2026, and median overall survival had not been reached, as highlighted by GlobeNewsWire. The planned Alpha DaRT sources were deployed in all eight patients, with no unanticipated serious adverse events. The three newer responses still require confirmation on subsequent scans, as highlighted by Benzinga.
Seeking Alpha maintains a Buy rating on Alpha Tau Medical and points to a potential FDA approval for recurrent squamous cell skin cancer in the first half of 2027. It also reports responses in all nine evaluable patients in a combination with Keytruda. Seeking Alpha cautions that the small REGAIN sample supports safety and feasibility rather than proving efficacy.
Alpha Tau Medical has a trailing price-to-earnings ratio of -11.55 and an earnings yield of -8.47%. Its enterprise value-to-operating cash flow ratio is -41.33, while its debt-to-equity ratio is 0.34 and its current ratio is 11.09.
Market news, earnings, and analyst coverage
Tony Dante writes market news and earnings coverage for the FMP blog, reporting on quarterly results, analyst rating changes, and company developments. His posts turn timely market events into concise, data-backed analysis for readers tracking individual names and sectors.
Financial data for every need
Real-time quotes and 30+ years of historical data, including prices, fundamentals, and insider transactions — all accessible via API.
Create Free Account